tiprankstipranks
Advertisement
Advertisement

e.l.f., Crown Castle, DoorDash, Stag, Tenaya Shake-Up

e.l.f., Crown Castle, DoorDash, Stag, Tenaya Shake-Up

Insiders have been trading these 5 stocks: ((ELF)), ((CCI)), ((DASH)), ((STAG)) and ((TNYA)). Here is a breakdown of their recent trades and their value.

Claim 30% Off TipRanks

Director Matthew Farrell just put real money behind his conviction in e.l.f. Beauty, scooping up 5,000 shares in a single insider purchase. The buy, worth $464,800, signals notable confidence in the company’s future trajectory and will catch the eye of investors tracking executive skin-in-the-game moves.

At Crown Castle, the tone is very different as key executives are heading for the exit, at least with some shares. EVP & GC Edward B JR Adams unloaded 4,650 shares for $401,481, while VP & Controller Robert Sean Collins sold 3,000 shares worth $262,470, moves that may prompt questions about near-term expectations.

DoorDash is seeing a wave of insider selling that stands out for both size and breadth of participation. From CAO Gordon Lee’s 2,693 shares at $472,594 to President & COO Prabir Adarkar’s 15,692 shares at $2,753,789 and CFO Ravi Inukonda’s 15,443 shares at $2,710,092, insiders including directors Stanley Tang and Andy Fang collectively moved millions, capped by CBO Keith Yandell and GC & Secretary Tia Sherringham selling $864,814 and $1,464,639 of stock.

Stag Industrial is also in the spotlight as multiple top leaders trimmed their stakes in sizable chunks. Director Virgis Colbert sold 18,000 shares for $685,399, CEO & President William Crooker exited 93,732 shares for $3,671,482, and EVP, CFO & Treas Pinard Matts sold 25,242 shares worth $988,729, a cluster of sales that could influence sentiment around the REIT.

Tenaya Therapeutics saw its largest moves from a single powerful player, as significant shareholder COLUMN GROUP III GP, LP dramatically cut back its position. The firm sold 4,170,266 shares for $2,368,270 and then followed up with another 829,734 shares for $500,017, signaling an aggressive step-down in exposure that biotech investors will scrutinize closely.

Disclaimer & DisclosureReport an Issue

1